Analysts forecast that TapImmune Inc. (NASDAQ:MRKR) will post earnings per share (EPS) of ($0.13) for the current quarter, Zacks reports. Zero analysts have made estimates for TapImmune’s earnings. TapImmune posted earnings per share of ($0.41) during the same quarter last year, which would indicate a positive year over year growth rate of 68.3%. The company is scheduled to announce its next quarterly earnings report on Thursday, August 8th.
On average, analysts expect that TapImmune will report full-year earnings of ($0.53) per share for the current financial year, with EPS estimates ranging from ($0.58) to ($0.48). For the next financial year, analysts forecast that the business will report earnings of ($0.52) per share, with EPS estimates ranging from ($0.75) to ($0.39). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow TapImmune.
TapImmune (NASDAQ:MRKR) last announced its earnings results on Thursday, May 9th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.05.
MRKR traded up $0.21 during mid-day trading on Wednesday, reaching $6.30. 909,672 shares of the company traded hands, compared to its average volume of 332,479. The firm has a market cap of $286.55 million, a PE ratio of -3.77 and a beta of 0.04. The company has a current ratio of 19.73, a quick ratio of 19.73 and a debt-to-equity ratio of 0.01. TapImmune has a 52-week low of $4.18 and a 52-week high of $13.55.
An institutional investor recently raised its position in TapImmune stock. Riggs Asset Managment Co. Inc. raised its stake in shares of TapImmune Inc. (NASDAQ:MRKR) by 68.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 45,919 shares of the company’s stock after buying an additional 18,650 shares during the period. Riggs Asset Managment Co. Inc. owned about 0.10% of TapImmune worth $303,000 as of its most recent SEC filing. 33.64% of the stock is currently owned by institutional investors.
TapImmune Company Profile
Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets.
Recommended Story: What is a Special Dividend?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TapImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TapImmune and related companies with MarketBeat.com's FREE daily email newsletter.